Rhenium Complexes with Red-Light-Induced Anticancer Activity.

Area of Science:

• Inorganic Chemistry
• Photochemistry
• Medicinal Chemistry

Background:

• Rhenium(I) complexes are explored for therapeutic applications.
• Photodynamic therapy (PDT) utilizes light-activated compounds to generate reactive oxygen species for cancer treatment.
• Protein kinase inhibitors are crucial in targeted cancer therapy.

Purpose of the Study:

• To synthesize and characterize novel Rhenium(I) pyridocarbazole complexes.
• To investigate the photoinduced antiproliferative activity of these complexes.
• To evaluate their potential as dual-function therapeutic agents combining PDT and kinase inhibition.

Main Methods:

• Synthesis and characterization of rhenium(I) pyridocarbazole complexes.
• Assessment of cytotoxicity in the dark and upon red light irradiation (λ ≥ 620 nm).
• Evaluation of singlet oxygen generation.
• In vitro protein kinase inhibition assays (e.g., Pim1 kinase).

Main Results:

• The synthesized rhenium(I) complexes exhibit significant antiproliferative activity upon red light irradiation.
• Cell death is mediated by the generation of singlet oxygen.
• These complexes demonstrate potent inhibition of protein kinases, with nanomolar IC50 values against Pim1.
• Minimal cytotoxicity was observed in the absence of light.

Conclusions:

• Rhenium(I) pyridocarbazole complexes are effective photodynamic agents generating singlet oxygen.
• These complexes possess dual-action potential, combining photodynamic therapy with protein kinase inhibition.
• This class of compounds represents a promising strategy for single-drug dual-function antiproliferative therapy.